Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCRX.L Regulatory News (CRX)

  • There is currently no data for CRX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) Cyprotex Plc

2 Nov 2016 10:09

RNS Number : 1336O
Nplus1 Singer Capital Markets Ltd
02 November 2016
 

FORM 8.5 (EPT/RI)

 

This disclosure replaces RNS 4994N which was disclosed in error.

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Nplus1 Singer Capital Markets Limited

 

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Cyprotex Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Cyprotex Plc

 

(d) Date dealing undertaken:

01 November 2016

 

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

NO

 

If YES, specify which:

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

 

ORD 1P

 

Purchase

 

11653

 

 

156.64p

 

156.64p

 

 

 (b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

Date of disclosure:

02 November 2016

Contact name:

Damian Fernandez

Telephone number:

020 7496 3093

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERBTBMTMBMMBFF
Date   Source Headline
10th Oct 20142:36 pmRNSShare Allotment CLN Final
9th Oct 20147:00 amRNSExpansion of Drug Transporter Capabilities
1st Oct 20147:00 amRNSExpansion of Toxicology Capabilities
9th Sep 20147:00 amRNSLaunch of KeratinoSensTM Service
4th Sep 20147:00 amRNSCyprotex joins CiPA initiative
29th Aug 20144:28 pmRNSListing of Loan Notes on Cayman Stock Exchange
28th Aug 20147:00 amRNSInterim Results 2014
21st Aug 20147:00 amRNSListing of Loan Notes on Cayman Stock Exchange
14th Aug 20143:30 pmRNSHolding(s) in Company
24th Jul 201412:15 pmRNSResult of AGM, GM & Further re Share Consolidation
3rd Jul 20147:00 amRNSProposed Share Consolidation & Notice of GM
1st Jul 20147:00 amRNSExpansion of Bioanalytical Capabilities
4th Jun 201411:44 amRNSDirector/PDMR Shareholding
16th Apr 201411:31 amRNSGrant of Options
25th Mar 20147:00 amRNSFinal Results
13th Mar 20144:57 pmRNSHolding(s) in Company
28th Jan 201410:46 amRNSGrant Options
28th Jan 201410:15 amRNSgrant of options
27th Jan 20144:52 pmRNSHolding(s) in Company
27th Jan 20144:19 pmRNSHolding(s) in Company
23rd Jan 20147:01 amRNSExecutive option scheme
23rd Jan 20147:00 amRNSTrading Update
2nd Jan 20147:00 amRNSAcquisition of CeeTox
19th Dec 20139:56 amRNSHolding(s) in Company
25th Nov 20139:48 amRNSDirector Dealing
5th Nov 20131:33 pmRNSReplacement: Holding(s) in Company
5th Nov 20139:44 amRNSHolding(s) in Company
5th Nov 20139:36 amRNSHolding(s) in Company
1st Oct 20131:36 pmRNSHolding(s) in Company
30th Sep 201311:43 amRNSHolding(s) in Company
26th Sep 201310:22 amRNSResult of GM & Board changes
3rd Sep 20137:00 amRNSPublication of Circular
21st Aug 20137:00 amRNSSubscription Agreement
15th Aug 20139:04 amRNSHolding(s) in Company
7th Aug 20137:00 amRNSHalf Yearly Report
24th Jul 20131:39 pmRNSDirectorate Change
18th Jul 20137:00 amRNSLaunch of new eCiphrNeuro service
17th Jul 20133:08 pmRNSResult of AGM
11th Jul 20137:00 amRNSLaunch of New Toxicity Guide
4th Jul 201310:09 amRNSHolding(s) in Company
2nd Jul 20132:09 pmRNSHolding(s) in Company
27th Jun 20134:36 pmRNSDirector/PDMR Shareholding
27th Jun 20132:30 pmRNSHolding(s) in Company
27th Jun 20132:30 pmRNSHolding(s) in Company
27th Jun 20132:30 pmRNSHolding(s) in Company
20th Jun 20137:00 amRNSTrading update
4th Jun 20137:00 amRNSIssue of Equity
21st May 20132:06 pmRNSHolding(s) in Company
21st May 20132:05 pmRNSHolding(s) in Company
1st May 20137:00 amRNSContract with U.S. EPA

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.